Activity of tobramycin in combination with clarithromycin

Slides:



Advertisements
Similar presentations
5/20/2015ISAP Is the cellular accumulation of antibiotics a predictive factor for intracellular efficacy ? Sandrine Lemaire Université catholique.
Advertisements

Screening for new antibiotics
IN THE NAME OF ALLAH ALMIGHTY THE MOST COMPASSIONATE THE MERCIFUL.
Biofilm-Grown Burkholderia cepacia Complex Cells Survive Antibiotic Treatment by Avoiding Production of Reactive Oxygen Species Kevin Wyllie and Veronica.
Antibiotics Basmah almaarik
Bacterial persistence
Setting-up a model of intracellular infection by Pseudomonas aeruginosa for the pharmacodynamic evaluation of antibiotic activity. J. Buyck1, O. Jolois2,
studies with Caco-2 cells and THP-1 macrophages
Activities of Daptomycin (DAP), Vancomycin (VAN) and Linezolid (LDZ) alone or in combination with Fusidic acid (FUS) in an in vitro dynamic model of.
A-052 Antibiotic (AB) activity against Pseudomonas aeruginosa (PA) with Normal or Mucoïd Phenotypes in an Artificial Sputum Medium (ASM) in vitro Biofilm.
Introduction Results Aim of the study Methods References Conclusion
Comparison of the intracellular and extracellular activities of approved and novel antistaphylococcal antibiotics using a pharmacodynamic model exploring.
A small molecule candidate for antibiotic co-therapy in the fight against persistence Valerie Defraine1, V. Liebens1, T. Swings1, R. Corbau2, A. Marchant2,
In vitro pharmacodynamic models for the study of antibiotic activity against bacterial biofilms Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire.
Frédéric Peyrusson, Françoise Van Bambeke, Paul M. Tulkens
Type III secretion system (TTSS) INTRODUCTION AND OBJECTIVES
Wafi Siala1,2, Françoise Van Bambeke1 , Thomas Vanzieleghem2
In vitro susceptibility of S
Activity of 9 antibiotics against intracellular forms of S. pneumoniae
P1058 Intracellular activity of antibiotics against a stable small colony variant (SCV) isolated from a CF patient in a model Calu-3 human airway epithelial.
Expression of Efflux system
8th International symposium on Antibiotic and Resistance,
Revealing moxifloxacin activity against biofilms of S
Can efflux confer high levels resistance to meropenem (MEM) in Pseudomonas aeruginosa (Pa) clinical isolates? H. Chalhoub1, H. Rodriguez-Villalobos2,
Introduction & Purpose Results Conclusions
FUS, VAN and LZD injected twice (T0 and T12); DAP injected once (T0).
This poster will be made available for download after the meeting at :
Epithelial lining fluid penetration of temocillin administered by continuous infusion in critically ill patients with nosocomial pneumonia. Visée C.1a,
Influence of antibiotic treatments on gene expression of RND efflux pumps in successive isolates of Pseudomonas aeruginosa collected from patients with.
Introduction Results Aim Methods References Conclusion
Co-medications Improve Moxifloxacin (MXF) Activity in Models of Pneumococcal Naïve and Induced Biofilms (BF) N. M. Vandevelde1, M. Van Obbergh1, P.M. Tulkens1,
Background and objectives
Comparative in vitro activity of temocillin and other β-lactams
Inhibitors of type three secretion system [TTSS] protect against Pseudomonas aeruginosa cellular toxicity by inhibiting the transcription of TTSS Mailing.
Table 2: Percentage of cross resistance among tested antibiotics
Emilien Drouot, Paul M. Tulkens, Françoise Van Bambeke
Julien Buyck, Paul M. Tulkens and Françoise Van Bambeke
Are Vitek2 system and E-test relevant and reliable for determining susceptibility to temocillin? Visée C.1, Frippiat F1, Descy J.2, Meex C.2, Melin P.2,
Julien Buyck, Paul M. Tulkens and Françoise Van Bambeke
Extracellular activity Intracellular activity
Staphylococcus aureus Streptococcus pneumoniae Pseudomonas aeruginosa
Abstract Results Methods Background Conclusions References
cellular accumulation (24h) Cstatic (LZD/RDZ ratio)
Incubation (with antibiotic)
52 - Antimicrobials Radezolid (RX-1741), a Novel Oxazolidinone, Accumulates Extensively within Human Macrophages and PMNs and Shows Activity towards.
Of a Pig-related ST-398 Methicillin-Resistant S. aureus (A-MRSA)
EV0626 Cellular pharmacokinetics of gepotidacin (GSK )
In vitro models for the study of antibiotic PK/PD in biofilms
Abstract Results Aim of the study Methods Background Conclusions
Difference log CFU from time 0
DISCUSSION AND CONCLUSION
INTRODUCTION METHODS CONCLUSIONS REFERENCES
Introduction Results Materials and Methods Conclusions
1200 Brussels - Belgium Temocillin is not substrate for OprD2 porin from Pseudomonas aeruginosa H. Chalhoub1,
Electron microscopy: intracellular infection of THP-1 by S. aureus
Log extracellular concentration (mg/L)
Susceptibility of Pseudomonas aeruginosa (P. a
Activity of Moxifloxacin against Staphylococcus aureus in Models of Persistent Infections (Intracellular Survival, Biofilms) Mailing address: P.M. Tulkens.
Jun Zhu, John J. Mekalanos  Developmental Cell 
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with.
Inhaled antibiotic therapy: What drug. What dose. What regimen
Intracellular models of infection to evaluate antibiotic activity
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with.
Setting-up of a 24 h model to evaluate the activity of antibiotics against intracellular forms of S. aureus infection C. Seral, M. Barcia-Macay, F. Van.
Biofilm Inhibitors that Target Amyloid Proteins
Dinty J. Musk, David A. Banko, Paul J. Hergenrother 
“Pulmonary infections”
Volume 22, Issue 2, Pages (February 2015)
Université catholique de Louvain, Brussels, Belgium
Presentation transcript:

Activity of tobramycin in combination with clarithromycin against Pseudomonas aeruginosa biofilms in an artificial sputum medium (ASM) model. Eugénie Bassères,1 Julien M. Buyck,1 Hamidou Traore,2 Paul M. Tulkens,1 Francis Vanderbist,2 and Françoise Van Bambeke.1 1 Pharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, 2 SMB Laboratories; Brussels, Belgium. 218 Contact: francoise.vanbambeke@uclouvain.be Introduction Biofilms are considered as a major reason for persistence of lung infection in cystic fibrosis patients. In this environment, P. aeruginosa are mucoid (a phenotype in which an extracellular matrix of alginate is being produced), sessile, and metabolically less active. This lifestyle confers a higher resistance to antibiotics compared to planktonic bacteria [1]. Among anti-pseudomonal antibiotics, the aminoglycoside tobramycin is one of those available for pulmonary administration, and therefore widely used for controlling infective exacerbations in cystic fibrosis patients. Macrolides are considered as inactive against P. aeruginosa, showing high MICs in standard medium (Mueller Hinton Broth, MHB). However, these antibiotics are often prescribed to cystic fibrosis patients, and improve their respiratory function. This positive effect is ascribed to non-antibiotic effects on the host (anti-inflammatory activity [2]) or on the bacteria (inhibition of quorum sensing [3]). Yet, it has been previously shown in our laboratory that macrolides regain activity on P. aeruginosa in media mimicking the infection site like bronchoalveolar lavage fluid [4]. In order to further investigate macrolide activity in cystic fibrosis, we developed a biofilm model with bacteria growing in an artificial medium mimicking the physico-chemical properties of the lung mucus during the disease (ASM; artificial sputum medium [5]). Indeed, the viscosity and components of this medium increase the ability of bacteria to attach to each other and to the surrounding surface, leading to biofilm formation. Aim To examine the effect of tobramycin and clarithromycin (as an exemplative macrolide) alone or in combination on biofilm formation eradication of preformed biofilms using in parallel the standard medium (MHB) and ASM a normal phenotype and a mucoid strain of P. aeruginosa Methods Strains: ATCC PAO1 and ATCC 39324 (stable mucoid). Biofilms were grown in 96 well-plates in ASM or Mueller Hinton Broth (MHB). ASM (1L): mucin 10g, DNA 4g, diethylene triamine pentaacetic acid 5.9mg, casaminoacids 5g, NaCl 4g, KCL 2.2g, tris base 1.81g, 5ml egg yolk emulsion. Antibiotic effect on biofilm formation was examined after 48 h incubation (drugs added at the time of inoculation). Antibiotic effect on mature biofilms was tested on 12-day old biofilms exposed during 48h to antibiotics (0.05 to 50 µg/mL tobramycin or/and 1 to 50 µg/mL clarithromycin). Biofilm biomass was evaluated by crystal violet staining and bacterial viability by fluorescein diacetate assay (6). Crystal violet Fluorescein DiAcetate The quantification of biofilm viability was based on bacteria ability to convert non-fluorescent fluorescein diacetate into highly fluorescent fluorescein by non-specific esterases. Crystal violet binds to negatively charged surface molecules and to polysaccharides in the extracellular matrix. It stains living and dead bacteria plus the matrix allowing the quantification of the biofilm biomass. Figure 2: Activity of tobramycin and clarithromycin in combination against 12-day old P. aeruginosa biofilms (wild-type and mucoid phenotypes) after 48 h incubation. Bars in yellow correspond to combinations of concentrations where a significant synergistic effect is observed. viability PAO1 39324 Results Table 1: Minimal Bactericidal Concentrations (MBCs) of antibiotics as measured in ASM or in CA-MHB medium MBC (mg/L) Tobramycin Clarithromycin PAO1 39324 ASM 5 50 ≥1024 MHB 0.5 ASM Tobramycin activity was decreased in ASM; clarithromyin was inactive in both media. Figure 1: Effect of tobramycin and clarithromycin on biofilm formation by PAO1 after 48 h of incubation ASM MHB biomass MHB PAO1 39324 ASM Biofilm formation was prevented by both antibiotics at subMBC concentrations in both media. Conclusion Although poorly active on planktonic bacteria, clarithromycin is as potent as tobramycin to impair biofilm formation, presumably due to its inhibitory effect on quorum sensing. Clarithromycin increases tobramycin activity against viability of P. aeruginosa (especially for a mucoid strain) growing in biofilms in a medium representative of cystic fibrosis patients’ sputum. These data further document that eukaryotic media can reveal specific anti-pseudomonal effects of macrolides; they also rationalize the interest of macrolide administration in cystic fibrosis patients. MHB Antibiotics alone were more active in MHB than in ASM and against viability than against biomass. Towards viability, a clear synergistic effect was observed when clarithromycin (any concentration) was combined with tobramycin at 5 or 50 µg/mL in ASM; this effect was less clear in CA-MHB where tobramycin was already highly effective alone. Towards biomass, combining clarithromycin to tobramycin did not bring significant improvement in activity. References (1) Ciofu et al, FEMS Immunol Med Microbiol. 2012;65:215-25 (2) Labro; J Antimicrob Chemother 1998; 41(Suppl B):37–46 (3) Yousef and Jaffe, Paediatr Respir Rev 2010; 11:108–14 (4) Buyck et al, Clin Infect Dis 2012; 55:534-42 (5) Sriramulu et al, J Med Microbiol 2005; 54(Pt7):667-76 (6) Wanandy et al, J Microbiol Methods 2005;60:21-30 This poster will be made available for download after the meeting at : www.facm.ucl.ac.be/posters